Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q1 FY25 results · Apr–Jun 2024
Bliss GVS Pharma reported revenue from operations of ₹183.64 crore (up 15.1% from Q1 FY24) and net profit of ₹22.11 crore (up 53.8% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 183.64 | 159.52 | +15.1% | 198.13 | −7.3% |
| Other income | 4.12 | 5.11 | −19.4% | 5.60 | −26.4% |
| Total income | 187.77 | 164.63 | +14.0% | 203.73 | −7.8% |
| Profit before tax | 30.07 | 21.65 | +38.9% | (3.95) | Turned profit |
| Net profit for the period | 22.11 | 14.37 | +53.8% | (4.91) | Turned profit |
| Attributable to shareholders of the company | 20.70 | 14.69 | +40.9% | (9.15) | Turned profit |
| EPS, basic (₹) | 1.97 | 1.41 | +39.7% | (0.88) | Turned profit |
| Net margin (%) | 12.0 | 9.0 | -2.5 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 148.96 | 108.99 | +36.7% | 163.82 | −9.1% |
| Other income | 6.84 | 6.53 | +4.8% | 8.46 | −19.2% |
| Total income | 155.80 | 115.52 | +34.9% | 172.28 | −9.6% |
| Profit before tax | 26.15 | 10.90 | +139.8% | (15.23) | Turned profit |
| Net profit for the period | 19.42 | 7.50 | +159.1% | (11.46) | Turned profit |
| EPS, basic (₹) | 1.85 | 0.72 | +156.9% | (1.11) | Turned profit |
| Net margin (%) | 13.0 | 6.9 | -7.0 |
Consolidated
- Filed with BSE
- 20 Aug 2024, 15:18 IST
- Board meeting
- 24 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 Aug 2024, 15:18 IST
- Board meeting
- 24 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE